

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA

复星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

ANNOUNCEMENT

ELECTION OF EMPLOYEE REPRESENTATIVE SUPERVISOR

The term of office of the seventh session of the supervisory committee (the “**Supervisory Committee**”) of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “**Company**”, together with its subsidiaries, the “**Group**”) will expire in June 2019 (or until the conclusion of the forthcoming annual general meeting (the “**AGM**”) to be held on 25 June, 2019 at which members of the new session of the Supervisory Committee (except for employee representative supervisors) will be elected). According to the articles of association of the Company, Ms. Ren Qian (“**Ms. Ren**”), being the employee representative supervisor of the existing session of the Supervisory Committee, was re-elected as an employee representative supervisor of the eighth session of the Supervisory Committee at the employee representatives meeting held on 10 May 2019. The biographical information of Ms. Ren is set out below:

Ms. Ren, aged 49. Ms. Ren joined the Group in May 2011 and served as the vice general manager and general manager of audit department of the Company from May 2011 up to the date hereof, and has served as the employee representative supervisor and the chairman of the Supervisory Committee since January 2018. Prior to joining the Company, Ms. Ren served as an auditor of the audit department of Shanghai No. 1 Department Store Company Limited* (上海市第一百貨股份有限公司) (whereafter merged with Shanghai Bailian Group Company Limited* (上海百聯集團股份有限公司), a company listed on the Shanghai Stock Exchange, stock code: 600827) and the manager of financial department of a subsidiary thereof from July 1991 to October 1999; the chief officer of the second division of audit department of China Worldbest Group Company Limited* (中國華源集團有限公司) from November 1999 to April 2006; the assistant to director of Shanghai Zhongzhou Certified Public Accountants Company Limited* (上海中洲會計師事務所有限公司) from May 2006 to September 2008; the deputy general manager of audit department of Shanghai China Fortune Company Limited* (上海華鑫股份有限公司) (a company listed on the Shanghai Stock Exchange, stock code: 600621) from October 2008 to April 2011. Ms. Ren graduated from Shanghai University of Finance and Economics* (上海財經大學) with a bachelor degree in economics in July 1991, and graduated from The Chinese University of Hong Kong with a master degree in accounting in November 2016.

As at the date of this announcement, Ms. Ren has not entered into a service contract with the Company as an employee representative supervisor of the eighth session of the Supervisory Committee. Ms. Ren will be appointed as the employee representative supervisor of the eighth session of the Supervisory Committee with a term of office of three years commencing from the date of the AGM. The remuneration of Ms. Ren will be determined primarily based on the economic benefits received by the Company and by reference to other factors including her responsibilities and actual performance as well as the remuneration standards of the industry.

Ms. Ren has confirmed that, save as disclosed above, as at the date of this announcement, she does not have any relationship with any directors (the “**Directors**”), senior management or substantial shareholders of the Company, and does not hold any other positions in the Company or any subsidiaries of the Company nor any other directorships in listed public companies in the last three years.

To the best knowledge of the Directors, as at the date of this announcement, Ms. Ren has personal interest in 17,250 A shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance, representing approximately 0.001% of the total number of issued A shares of the Company and approximately 0.001% of the total number of shares of the Company in issue. Save as disclosed above, Ms. Ren does not have any interests or short positions in any shares, underlying shares or debentures of the Company within the meaning of Part XV of the Securities and Futures Ordinance as at the date of this announcement.

Save as disclosed above, there is no other information required to be disclosed pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. There are no matters concerning Ms. Ren that need to be brought to the attention of the Shareholders.

The eighth session of the Supervisory Committee will consist of Ms. Ren as the employee representative supervisor, Mr. Cao Genxing and Mr. Guan Yimin (subject to the shareholders’ approval at the AGM).

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Qiyu
Chairman

Shanghai, People’s Republic of China

10 May 2019

As at the date of this announcement, the executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang and Mr. Wu Yifang; the non-executive directors of the Company are Mr. Wang Qunbin, Mr. Wang Can, Ms. Mu Haining and Mr. Zhang Xueqing; and the independent non-executive directors of the Company are Mr. Cao Huimin, Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin and Mr. Wai Shiu Kwan Danny.

* *for identification purposes only*